Crosstalk Bio Overview
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Crosstalk Bio General Information
Description
Developer of novel therapeutics designed to target tissue-resident immune cells for the treatment of autoimmune and inflammatory diseases. The company develops therapies that modulate tissue-resident immune cells, enabling targeted treatment of immune-mediated conditions.
Contact Information
Corporate Office
- Somerville, MA
- United States
Corporate Office
- Somerville, MA
- United States
Crosstalk Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Aug-2026 | Completed | Startup |
Crosstalk Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Crosstalk Bio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mass General Brigham Ventures | Venture Capital | Minority |
Crosstalk Bio FAQs
-
Where is Crosstalk Bio headquartered?
Crosstalk Bio is headquartered in Somerville, MA.
-
What industry is Crosstalk Bio in?
Crosstalk Bio’s primary industry is Biotechnology.
-
Is Crosstalk Bio a private or public company?
Crosstalk Bio is a Private company.
-
What is Crosstalk Bio’s current revenue?
The current revenue for Crosstalk Bio is .
-
Who are Crosstalk Bio’s investors?
Mass General Brigham Ventures has invested in Crosstalk Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
